Another line of evidence pointing to upregulated BDNF signaling in FXS comes from recent studies demonstrating aberrant increases in matrix metalloprotease-9 (MMP9) levels in brains of FXS patients and Fmr1 KO mice (Gkogkas et al., 2014). The gene discussed is MMP9; the disease is fragile X syndrome.